Citizens National Bank Trust Department Sells 385 Shares of Johnson & Johnson (NYSE:JNJ)

Citizens National Bank Trust Department decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 56,254 shares of the company’s stock after selling 385 shares during the period. Johnson & Johnson comprises approximately 1.9% of Citizens National Bank Trust Department’s holdings, making the stock its 9th biggest holding. Citizens National Bank Trust Department’s holdings in Johnson & Johnson were worth $9,117,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Donaldson Capital Management LLC grew its position in shares of Johnson & Johnson by 2.1% during the 3rd quarter. Donaldson Capital Management LLC now owns 343,944 shares of the company’s stock valued at $55,740,000 after buying an additional 7,092 shares during the last quarter. Robeco Institutional Asset Management B.V. grew its position in shares of Johnson & Johnson by 2.6% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 1,390,984 shares of the company’s stock valued at $225,423,000 after buying an additional 35,717 shares during the last quarter. Lansing Street Advisors grew its position in shares of Johnson & Johnson by 1.8% during the 3rd quarter. Lansing Street Advisors now owns 5,607 shares of the company’s stock valued at $909,000 after buying an additional 101 shares during the last quarter. BSW Wealth Partners grew its position in shares of Johnson & Johnson by 2.2% during the 3rd quarter. BSW Wealth Partners now owns 6,738 shares of the company’s stock valued at $1,092,000 after buying an additional 143 shares during the last quarter. Finally, Angeles Wealth Management LLC boosted its stake in Johnson & Johnson by 22.2% during the 3rd quarter. Angeles Wealth Management LLC now owns 15,837 shares of the company’s stock valued at $2,567,000 after purchasing an additional 2,877 shares during the period. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Down 1.2 %

JNJ stock opened at $158.24 on Tuesday. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $168.85. The company’s 50 day simple moving average is $163.18 and its 200-day simple moving average is $155.68. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The firm has a market capitalization of $380.98 billion, a P/E ratio of 22.90, a P/E/G ratio of 2.84 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, beating the consensus estimate of $2.21 by $0.21. The firm had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The company’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.66 EPS. As a group, equities research analysts anticipate that Johnson & Johnson will post 9.94 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be given a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.13%. The ex-dividend date is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio is 71.78%.

Insiders Place Their Bets

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the sale, the vice president now directly owns 18,973 shares of the company’s stock, valued at $3,131,683.38. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

JNJ has been the subject of a number of analyst reports. Royal Bank of Canada boosted their target price on shares of Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research note on Wednesday, October 16th. Daiwa America lowered shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. The Goldman Sachs Group reduced their price target on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research note on Friday, July 19th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 14th. Finally, Daiwa Capital Markets lowered shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and reduced their price target for the stock from $160.00 to $150.00 in a research note on Tuesday, July 23rd. Six investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $175.93.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.